GSA Capital Partners LLP Invests $292,000 in LivaNova PLC (NASDAQ:LIVN)

GSA Capital Partners LLP bought a new position in LivaNova PLC (NASDAQ:LIVN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,561 shares of the company’s stock, valued at approximately $292,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LIVN. State Board of Administration of Florida Retirement System lifted its position in LivaNova by 13.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 17,542 shares of the company’s stock valued at $981,000 after purchasing an additional 2,060 shares during the period. Vanguard Group Inc. increased its holdings in LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock valued at $102,537,000 after buying an additional 62,480 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in LivaNova during the first quarter valued at approximately $94,000. Lazard Asset Management LLC purchased a new stake in shares of LivaNova in the first quarter worth $84,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of LivaNova by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,980 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LIVN. Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, November 12th. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Finally, The Goldman Sachs Group assumed coverage on shares of LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Trading Down 0.7 %

Shares of LIVN opened at $51.32 on Friday. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a 50-day moving average of $52.13 and a 200 day moving average of $52.60. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of 122.19 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.